Beyond striae cutis: A case report on how physical skin complaints unveiled end-of-life total experience.

BACKGROUND: End-of-life is a unique and multidimensional experience, and physical complaints can reveal other areas of distress. METHOD: A case report of a woman with terminal cancer with painful and deforming skin striae cared by a multidisciplinary team. RESULTS: After initially treating her physical pain, other end-of-life psychosocial, spiritual, and existential aspects could be addressed. SIGNIFICANCE OF RESULTS: Physical distress can unveil other essential areas of end-of-life experience when multidisciplinary teams caring for the terminally ill patients use holistic approaches.

Diffuse neurofibroma--an uncommon cause of alopecia.

Although infrequent, alopecia can be caused by benign cutaneous tumours. Neurofibromas are common benign tumors that originate in the peripheral nerve sheath. Diffuse neurofibroma is a rare variant of neurofibroma that is thought to occur mainly in the head and neck of children and young adults. Histology generally shows an infiltrative tumor, composed of spindle cells in the dermis and subcutaneous tissue. Despite being rare, malignant transformation has been reported. The association between diffuse neurofibromas and neurofibromatosis type 1 still remains to be determined since some authors question the low incidence usually described. We report the case of a 42-year-old man who had a diffuse neurofibroma on the scalp presenting as alopecic plaques.

Diffuse neurofibroma - an uncommon cause of alopecia / Neurofibroma difuso - uma causa rara de alopecia

Although infrequent, alopecia can be caused by benign cutaneous tumours. Neurofibromas are common benign tumors that originate in the peripheral nerve sheath. Diffuse neurofibroma is a rare variant of neurofibroma that is thought to occur mainly in the head and neck of children and young adults. Histology generally shows an infiltrative tumor, composed of spindle cells in the dermis and subcutaneous tissue. Despite being rare, malignant transformation has been reported. The association between diffuse neurofibromas and neurofibromatosis type 1 still remains to be determined since some authors question the low incidence usually described. We report the case of a 42-year-old man who had a diffuse neurofibroma on the scalp presenting as alopecic plaques.

Apesar de infrequente, a alopecia pode ser causada por tumores cutâneos benignos. Os neurofibromas são neoplasias benignas comuns com origem na baínha externa dos nervos. O neurofibroma difuso é uma variante rara de neurofibroma que ocorre tipicamente na cabeça e pescoço de crianças e adultos jovens. Histologicamente caracteriza-se por um tumor infiltrativo, composto por células fusiformes, localizado na derme e tecido celular subcutâneo. Apesar de rara, a transformação maligna já foi descrita. A associação dos neurofibromas difusos e neurofibromatose tipo 1 ainda não está determinada dado que alguns autores contestam a baixa incidência habitualmente referida. Descrevemos o caso de um homem de 42 anos com um neurofibroma difuso do couro cabeludo com aprasentacao de placas de alopecia.

Phototherapy for pityriasis lichenoides: our experience.

Pityriasis lichenoides is a benign disease that includes a continuous spectrum with two polar ends: pityriasis lichenoides et varioliformis acuta (PLEVA) and pityriasis lichenoides chronica (PLC). Although its benign and self-limited character, treatment is required, both for itch relief and for cosmetic issues. The present study is a retrospective analysis of 13 patients (11 PLC and 2 PLEVA) treated in our institution with psoralen plus ultraviolet A (PUVA) or ultraviolet A combined with ultraviolet B (UVA/UVB) during the period 1998-2011. In the PUVA group, complete response was achieved in five patients and partial response in two. Total cumulative UVA dose was 84.4 J/cm(2). One patient quit therapy without therapeutic response. In the UVA/UVB group, complete response was achieved in two patients and partial response in an equal number of patients. One patient did not reach a significant improvement. Total cumulative doses were: 26.1 J/cm(2) for UVA and 3.62 J/cm(2) for UVB. There were no acute side effects in either therapeutic group. In the present study, PUVA phototherapy was preferred for patients with more widespread or long-evolving disease, while UVA/UVB was selected for patients who presented more recent disease or contraindications for PUVA therapy. Regardless of the absence of clinical guidelines, both therapeutic options proved to be successful, ascertaining phototherapy as an effective and safe option for pityriasis lichenoides patients.

Psoriasis triggered by tetanus-diphtheria vaccination.

Psoriasis is a common inflammatory disease with multiple known triggers. We report the case of a patient whose psoriasis was triggered by tetanus and diphtheria immunization (Td vaccine). To the best of our knowledge, this is the first reported case of psoriasis triggered by the Td vaccine. Authors speculate about the involved mechanisms.

Sensitization to methylisothiazolinone in a group of methylchloroisothiazolinone/methylisothiazolinone allergic patients.

In the EU, Methylisothiazolinone (MI) was approved as a preservative in cosmetics and household products in 2005. Since then, several cases of MI contact allergy have been reported. We studied the prevalence of MI sensitization in patients allergic to Methylchloroisothiazolinone/Methylisothiazolinone (MCI/MI). From a total of 751 patients submitted to patch testing between 2007 and 2011, 26 were sensitized to MCI/MI 100 ppm aq. Fifteen patients were retested with MCI/MI 100 ppm aq, MI 200 ppm aq and personal products, and the relevance of positive results, concerning the use of personal products, was evaluated. Seven of the 15 MCI/MI positive patients were positive to MI: six patients showed an equally intense reaction to MCI/MI and MI alone, and another one presented with a stronger reaction to the latter compound. All positive reactions were relevant. The use of MI alone as a preservative does not seem to be a safe alternative. In this study, the majority of positive reactions to MCI/MI and MI had similar intensity, although primary sensitization to MI has to be considered according to each individual case; moreover, primary sensitization to MCI with cross-reactivity to MI cannot be excluded. Further studies are needed to determine the optimal concentration for MI patch testing.